Q32 Bio Inc. has announced that it received a notice from the Nasdaq Stock Market LLC on May 19, 2025, indicating that the company is no longer in compliance with the minimum stockholders' equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market. The company's recent financial report showed a stockholders' equity deficit of approximately $4.0 million. Additionally, Q32 Bio failed to meet alternative criteria, such as a market value of listed securities of $35.0 million or net income from continuing operations of $0.5 million. This situation arose partly due to the accounting impact of re-acquiring bempikibart from Amgen Inc. Q32 Bio now has 45 days to submit a compliance plan to Nasdaq. If accepted, Nasdaq may grant an extension of up to 180 days for Q32 Bio to meet the listing requirements. Meanwhile, the company's stock will continue trading on Nasdaq under the symbol "QTTB."
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。